Pulmonary microvascular lesions regress in reperfused chronic thromboembolic pulmonary hypertension.

[1]  M. Humbert,et al.  Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature , 2014, European Respiratory Journal.

[2]  Nicholas W Morrell,et al.  Relevant issues in the pathology and pathobiology of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[3]  E. Fadel,et al.  Piglet Model of Chronic Pulmonary Hypertension , 2013, Pulmonary circulation.

[4]  E. Fadel,et al.  Chronic thromboembolic pulmonary hypertension: animal models , 2013, European Respiratory Journal.

[5]  Robin Shandas,et al.  High pulsatility flow stimulates smooth muscle cell hypertrophy and contractile protein expression. , 2013, American journal of physiology. Lung cellular and molecular physiology.

[6]  M. Yeager,et al.  Endothelin-1, the unfolded protein response, and persistent inflammation: role of pulmonary artery smooth muscle cells. , 2012, American journal of respiratory cell and molecular biology.

[7]  E. Fadel,et al.  Right lung ischemia induces contralateral pulmonary vasculopathy in an animal model. , 2012, The Journal of thoracic and cardiovascular surgery.

[8]  F. Clubb,et al.  Swine as Models in Biomedical Research and Toxicology Testing , 2012, Veterinary pathology.

[9]  P. Dartevelle,et al.  Surgical treatment of chronic thromboembolic pulmonary hypertension. , 2000, Canadian respiratory journal.

[10]  J. Barberà,et al.  Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results From an International Prospective Registry , 2011, Circulation.

[11]  W. Klepetko,et al.  Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. , 2011, The Journal of thoracic and cardiovascular surgery.

[12]  T. Satoh,et al.  Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension , 2010, International journal of rheumatology.

[13]  I. Lang.  Advances in understanding the pathogenesis of chronic thromboembolic pulmonary hypertension , 2010, British journal of haematology.

[14]  B. Housset,et al.  Role for interleukin-6 in COPD-related pulmonary hypertension. , 2009, Chest.

[15]  Robin Shandas,et al.  Effects of Pathological Flow on Pulmonary Artery Endothelial Production of Vasoactive Mediators and Growth Factors , 2009, Journal of Vascular Research.

[16]  E. Fadel,et al.  Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. , 2009, The Journal of thoracic and cardiovascular surgery.

[17]  T. Nawrot,et al.  C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[18]  B. Andersson,et al.  Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension , 2009, European Respiratory Journal.

[19]  E. Mark,et al.  Interleukin-6 Overexpression Induces Pulmonary Hypertension , 2009, Circulation research.

[20]  S. Eddahibi,et al.  Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice , 2009, Respiratory research.

[21]  M. Humbert,et al.  Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. , 2008, American journal of respiratory and critical care medicine.

[22]  John Jenkins,et al.  Inflammation and ischemia-induced lung angiogenesis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[23]  R. Lutter,et al.  Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[24]  T. Kishimoto,et al.  Interleukin-6 : discovery of a pleiotropic cytokine , 2022 .

[25]  E. Fadel,et al.  Regression of the systemic vasculature to the lung after removal of pulmonary artery obstruction. , 2006, American journal of respiratory and critical care medicine.

[26]  H. Schäfers,et al.  Circulating big endothelin-1: an active role in pulmonary thromboendarterectomy? , 2005, The Journal of thoracic and cardiovascular surgery.

[27]  I. Salmon,et al.  Signaling Molecules in Overcirculation-Induced Pulmonary Hypertension in Piglets: Effects of Sildenafil Therapy , 2004, Circulation.

[28]  Gérald Simonneau,et al.  Chronic thromboembolic pulmonary hypertension , 2004, European Respiratory Journal.

[29]  E. Fadel,et al.  Regression of postobstructive vasculopathy after revascularization of chronically obstructed pulmonary artery. , 2004, The Journal of thoracic and cardiovascular surgery.

[30]  H. Morita,et al.  Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. , 2004 .

[31]  A. Branzi,et al.  The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.

[32]  Ori Ben-Yehuda,et al.  Preoperative Partitioning of Pulmonary Vascular Resistance Correlates With Early Outcome After Thromboendarterectomy for Chronic Thromboembolic Pulmonary Hypertension , 2004, Circulation.

[33]  M. Humbert,et al.  SERIES "ADVANCES IN PATHOBIOLOGY, DIAGNOSIS, AND TREATMENT OF PULMONARY HYPERTENSION" Edited by A.T. Dinh-Xuan, M. Humbert, R. Naeije Number 10 in this Series Chronic thromboembolic pulmonary hypertension , 2004 .

[34]  P. Thistlethwaite,et al.  Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. , 2003, The Annals of thoracic surgery.

[35]  W. Mitzner,et al.  Identification of genes promoting angiogenesis in mouse lung by transcriptional profiling. , 2003, American journal of respiratory cell and molecular biology.

[36]  C. Pedersen,et al.  Pulmonary vascular remodeling distal to pulmonary artery ligation is accompanied by upregulation of endothelin receptors and nitric oxide synthase. , 2000, Experimental lung research.

[37]  R. Michel,et al.  Endothelin reactivity and receptor profile of pulmonary vessels in postobstructive pulmonary vasculopathy. , 1997, American journal of physiology. Heart and circulatory physiology.

[38]  N. Charan,et al.  Angiogenesis in bronchial circulatory system after unilateral pulmonary artery obstruction. , 1997, Journal of applied physiology.

[39]  M. Humbert,et al.  Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. , 1995, American journal of respiratory and critical care medicine.

[40]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[41]  R. Michel,et al.  Increased resistance in postobstructive pulmonary vasculopathy: structure-function relationships. , 1991, Journal of applied physiology.

[42]  J. Edwards,et al.  The Pathology of Hypertensive Pulmonary Vascular Disease: A Description of Six Grades of Structural Changes in the Pulmonary Arteries with Special Reference to Congenital Cardiac Septal Defects , 1958, Circulation.